
Galinpepimut-S Improves OS in AML in Second or Later Remission
Key Takeaways
- Median overall survival improved to 24.0 months with GPS versus 14.7 months with best available treatment (HR 0.59; P=.035) in transplant-ineligible AML patients after ≥2nd remission.
- Mechanistically, four WT1-derived peptides (modified short, native long, modified long) are designed to broaden antigen-specific CD8+ and CD4+ T-cell immunity while preserving recognition of native WT1.
Galinpepimut-S (GPS) administered as maintenance therapy improved overall survival (OS) compared with best available treatment (BAT) in patients with acute myeloid leukemia (AML) in second or later remission who were not candidates for transplant, meeting the primary end point of the phase 3 REGAL trial (NCT04229979).1
Data announced by SELLAS Life Sciences showed that at the final analysis, which was triggered by the prespecified 80th death, the median OS was 24.0 months with GPS vs 14.7 months with BAT (HR, 0.59; 2-sided P = .035).
“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in OS for patients with AML who have very limited options after achieving a second remission. The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for SELLAS and provides Phase 3 validation of our WT1-targeted immunotherapeutic technology,” Angelos Stergiou, MD, ScD hc, president and chief executive officer of SELLAS Life Sciences, stated in a news release. "We also believe GPS has the potential to become an important paradigm-shifting option for this high-risk population that desperately needs effective therapies. Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible."
How does galinpepimut-S work?
GPS is an investigational peptide vaccine directed against WT1, a protein overexpressed in leukemic blasts. It combines 4 WT1-derived peptides: a modified short peptide meant to activate CD8-positive T cells, 2 native long peptides meant to elicit CD4-positive responses, and a modified long peptide meant to engage both T-cell subsets.
The peptide modifications are intended to enhance immune recognition while producing T cells that still recognize the native WT1 sequences present on leukemia cells. By engaging both CD4-positive and CD8-positive T cells, the vaccine aims to generate a broader antileukemic immune response. As maintenance therapy, the goal is to direct that response against residual WT1-expressing disease after remission.
How was the REGAL trial designed?
The international, open-label REGAL study enrolled patients who had reached a second or subsequent complete remission, including complete remission with incomplete platelet recovery, following salvage therapy and who could not proceed to allogeneic stem cell transplant.2
Patients needed to be at least 18 years of age, have an ECOG performance status of 0 to 3, and provide consent within 6 months of achieving remission. To qualify, patients needed fewer than 5% bone marrow blasts, no blasts in the peripheral blood, no extramedullary disease, an absolute neutrophil count greater than 1000/µL, and a platelet count greater than 20,000/µL. The trial excluded patients with acute promyelocytic leukemia, active central nervous system involvement, or a planned near-term transplant.2
Patients were randomly assigned 1:1 to receive GPS or investigator-chosen BAT.In the investigational arm, GPS was given subcutaneously along with Montanide adjuvant and sargramostim (Leukine). Patients received 6 doses at 2-week intervals, followed by booster doses spaced increasingly further apart; the trial registry also outlined continued maintenance dosing in years 2 and 3. In the control arm, investigators could select observation, azacitidine (Vidaza), decitabine (Dacogen), venetoclax (Venclexta), or low-dose cytarabine, as monotherapy or in allowed combinations.
OS served as the primary end point. Secondary end points included leukemia-free survival, survival rates at landmark time points, safety, and measurable residual disease. The published trial-design report listed Wilms tumor 1 (WT1)–specific T-cell responses as exploratory assessments.3
What safety findings and next steps were reported?
Most treatment-related adverse effects were grade 1 or 2, with injection-site reactions occurring most often, and no new safety concerns emerged.1
SELLAS intends to meet with the FDA and is preparing a biologics license application, with submission anticipated in the first half of 2027. The company also expects to present additional analyses at a medical meeting and publish them in a peer-reviewed journal.
References
- SELLAS Life Sciences announces positive pivotal phase 3 REGAL trial data showing immunotherapeutic cancer vaccine, galinpepimut-S (GPS), demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with acute myeloid leukemia. News release. SELLAS Life Sciences Group. November 17, 2026. Accessed November 17, 2026. https://www.globenewswire.com/news-release/2026/11/17/3404429/0/en/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunotherapeutic-cancer-vaccine-galinpepimut-s-gps-demonstrated-a-statistically-significant-and-cl.html
- Study of galinpepimut-S compared to best available therapy in patients with acute myeloid leukemia (REGAL). ClinicalTrials.gov. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT04229979
Related to this article







